Friday, May 1, 2026

South Korea Reports No Radiation Risk From Suspected North Korean Uranium Waste for Second Month

South Korean monitoring confirms no abnormalities in water quality near North Korea's uranium plant, alleviating contamination concerns.

Elon Musk Dances His Way to Victory at Tesla Shareholder Meeting!

WSJ reported that Tesla CEO Elon Musk celebrated his victory in a wage vote by dancing on the stage of the general meeting.

COMMUNISM CRUMBLES: Russia Pays North Korea $187K+ For Airspace—Money Over Ideology!

A Russian airline has begun using North Korean airspace, signaling potential economic ties, despite UN sanctions on financial transactions.

Tag: biosimilars

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Celltrion Launches New Autoimmune Drug Avtozma in Japan

Celltrion launches Avtozma for autoimmune diseases in Japan, expanding its product portfolio and strengthening market presence.

Celltrion’s Steqeyma IV Approval: What This Means for Celltrion’s Growth in Japan’s Autoimmune Drug Market

Celltrion's Steqeyma IV formulation gains approval in Japan, expanding treatment for Crohn's disease and enhancing market competitiveness.

Truxima: How the First Korean Biosimilar Achieved 35.8% Market Share in the U.S.!

Celltrion’s Truxima becomes South Korea's first biosimilar to lead U.S. prescription market, boosted by tariff exemptions and strong growth.

How Celltrion’s Local Production Strategy Eliminates U.S. Drug Tariffs Influence

Celltrion resolves tariff impacts on U.S. sales, boosting local production and growth opportunities for its biosimilars, including Zymfentra.

Samchundang Pharm Announces 250 Billion KRW Stake Sale…Expectations Rise for Future Growth

Samchundang Pharm's CEO plans a 2.5 billion KRW share sale for tax purposes, hinting at significant news and future growth in pharma.

Celltrion’s 1 Trillion KRW Investment: A Game Changer for Biopharmaceutical Production by 2030

Celltrion plans a major expansion with over 1 trillion KRW investment, boosting production capacity for biosimilars and new drugs by 2030.

Why Celltrion’s STEQEYMA Auto-Injector is a Game Changer for Autoimmune Patients in North America

Celltrion expands its Steqeyma auto-injector lineup in Canada, enhancing market competitiveness and patient accessibility in North America.

Celltrion’s Breakthrough: Why Vegzelma and Herzuma Lead in Japan’s Oncology Market

Celltrion's cancer treatments dominate the Japanese market, with Vegzelma and Herzuma capturing significant shares, showcasing strong growth.

How Celltrion Plans to Cut Biologics Development Costs by 25% Amid FDA Regulation Changes

Celltrion is optimistic about enhanced competitiveness due to eased biosimilar regulations by the FDA, expecting significant cost reductions.

Samsung Biologics: How a 56 Billion USD CDMO Leader is Shaping the Future of Biopharmaceuticals

Samsung Biologics is evolving as a leading CDMO, targeting a production capacity of 1.32M liters by 2030 after its spin-off from Bioepis.

CT-P55: How Celltrion’s New Biosimilar Approval Will Transform Clinical Trials in Europe

Celltrion receives EMA approval to reduce patient enrollment for CT-P55 trial, aiming to cut costs and duration of clinical development.

Celltrion Gets Global IB Upgrades: Morgan Stanley Raises Target to $206.25 as New Biosimilars Lift Margins

Celltrion is expanding through biosimilars and new drug development, attracting global investor interest and raising target stock prices.

Celltrion’s Zymfentra: How This Breakthrough Drug is Driving Record Sales

Celltrion expects record sales driven by Zymfentra's success, expanding into new biosimilars and CDMO business for future growth.

How Celltrion Plans to Expand Its Biosimilar Portfolio to 41 Products by 2038

Celltrion unveils its growth strategy at the JP Morgan Healthcare Conference, aiming to expand biosimilars and develop new drug pipelines.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.